Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Mar;65(3):348-51.
doi: 10.1002/ana.21601.

Sympathetic block with botulinum toxin to treat complex regional pain syndrome

Ian Carroll  1 , J David Clark, Sean Mackey
Affiliations
Randomized Controlled Trial

Sympathetic block with botulinum toxin to treat complex regional pain syndrome

Ian Carroll et al. Ann Neurol. 2009 Mar.

Abstract

Complex regional pain syndrome is a refractory pain condition with few tested therapies. We hypothesized that botulinum toxin A (BTA) would prolong analgesia after sympathetic blocks in patients with complex regional pain syndrome. We compared the duration of standard lumbar sympathetic block (LSB) with bupivacaine to LSB with bupivacaine and BTA in nine patients with refractory complex regional pain syndrome. Median time to analgesic failure was 71 (95% confidence interval, 12-253) days after LSB with BTA compared with fewer than 10 days (95% confidence interval, 0-12) after standard LSB (log-rank, p < 0.02). BTA profoundly prolonged the analgesia from sympathetic block in this preliminary study.

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: The authors report filing a patent for the use of botulinum toxins in sympathetic block.

Figures

Fig 1
Fig 1
Duration of analgesia. Analgesic duration of lumbar sympathetic block is extended by botulinum toxin type A (BTA). Black line represents bupivacaine; red line represents bupivacaine plus BTA. Median time to analgesic failure was 69 days after lumbar sympathetic block with BTA compared with fewer than 8 days among those receiving local anesthetic alone. Log-rank, p < 0.02.
Fig 2
Fig 2
Change in visual analog pain score (VAS) over time. Botulinum toxin type A (BTA) reduces VAS sores of pain intensity over protracted time periods in responders. Assignment to the BTA-enhanced lumbar sympathetic block was associated with a mean decrease in VAS of 1.6 points (95% confidence interval, 1.2–2.0; p < 0.0001). Patients appear to be BTA responders or nonresponders. Despite refractory long-standing pain, Patients 1, 2, and 7 experienced long-term significant reduction in pain. Note time scales for each patient and each injection differ because each patient recorded pain until they perceived they had returned to baseline. All injections occurred on day 7 after a 1-week “run-in” period. Black lines represent bupivacaine; red lines represent bupivacaine plus BTA. Patients 1 (A), 2 (B), 4 (C), 5 (D), 6 (E), 7 (F), 8 (G), and 9 (H).
See this image and copyright information in PMC

References

    1. Raja SN, Grabow TS. Complex regional pain syndrome I (reflex sympathetic dystrophy) Anesthesiology. 2002;96:1254–1260. - PubMed
    1. Sandroni P, Benrud-Larson LM, McClelland RL, Low PA. Complex regional pain syndrome type I: incidence and prevalence in Olmsted County, a population-based study. Pain. 2003;103:199–207. - PubMed
    1. de Mos M, de Bruijn AG, Huygen FJ, et al. The incidence of complex regional pain syndrome: a population-based study. Pain. 2007;129:12–20. - PubMed
    1. Mailis A, Furlan A. Sympathectomy for neuropathic pain. Cochrane Database Syst Rev. 2003 CD002918. - PubMed
    1. Sato J, Perl ER. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science. 1991;251:1608–1610. - PubMed

Publication types

Substances